

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 March 2023 (30.03.2023)



(10) International Publication Number
WO 2023/049369 A3

(51) International Patent Classification:

C07D 401/12 (2006.01) A61K 31/4433 (2006.01)
C07D 405/04 (2006.01) A61K 31/444 (2006.01)
C07D 413/14 (2006.01) A61K 31/4439 (2006.01)
C07D 405/14 (2006.01) A61K 31/443 (2006.01)
C07D 401/14 (2006.01) A61K 31/506 (2006.01)
C07D 405/12 (2006.01) A61P 25/08 (2006.01)

(21) International Application Number:

PCT/US2022/044566

(22) International Filing Date:

23 September 2022 (23.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/248,341 24 September 2021 (24.09.2021) US

(71) Applicant: **XENON PHARMACEUTICALS INC.**
[CA/CA]; 200 - 3650 Gilmore Way, Burnaby, British Co-
lumbia V5G 4W8 (CA).

(72) Inventors: **BURFORD, Kristen**; c/o Xenon Pharmaceu-
ticals, 200 - 3650 Gilmore Way, Burnaby, British Co-
lumbia V5G 4W8 (CA). **LOFSTRAND, Verner**; c/o
Xenon Pharmaceuticals, 200 - 3650 Gilmore Way, Burna-
by, British Columbia V5G 4W8 (CA). **KIM, Jung Yun**; c/o
Xenon Pharmaceuticals, 200 - 3650 Gilmore Way, Burnaby,
British Columbia V5G 4W8 (CA). **CLEMENT, Helen**; c/o
Xenon Pharmaceuticals, 200 - 3650 Gilmore Way, Burnaby,
British Columbia V5G 4W8 (CA). **CHARIFSON, Paul**; c/
o Xenon Pharmaceuticals, 200 - 3650 Gilmore Way, Burna-
by, British Columbia V5G 4W8 (CA). **CLARK, Michael**;
c/o Xenon Pharmaceuticals, 200 - 3650 Gilmore Way,
Burnaby, British Columbia V5G 4W8 (CA).

(74) Agent: **LIGON, Toby, J.** et al.; Seed Intellectual Proper-
ty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle,
Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

27 April 2023 (27.04.2023)

(54) Title: PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS



(I)

(57) Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, Z, R1, R2a, R2b, R3, and L are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

WO 2023/049369 A3